Zonisamide

Generic Name: Zonisamide

Brand Names: Zonegran, Zonisade, Zonisamide Mylan

Drug Type: Small Molecule

Chemical Formula: C_₈H_₈N_₂O_₃S

CAS Number: 68291-97-4

Unique Ingredient Identifier: 459384H98V

Background: Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory...

Indication: Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions: Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy

Not yet recruiting

Conditions: Epilepsies, Partial

Interventions: Drug: Zonisamide

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 400

Registration Number: NCT06374966

Locations: 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Huzhou Third People's Hospital, Huzhou, Zhejiang, China
🇨🇳
Jinhua Second hospital, Jinhua, Zhejiang, China

and more 7 locations

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Phase 3

Recruiting

Conditions: Smoking Cessation

Interventions: Drug: Bupropion
Drug: Placebo bupropion
Drug: Placebo zonisamide
Drug: Zonisamide
Other: E-cigarette

First Posted Date: 2022-01-25

Last Posted Date: 2024-08-15

Lead Sponsor: Rose Research Center, LLC

Target Recruit Count: 180

Registration Number: NCT05205811

Locations: 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

Phase 2

Recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2021-11-26

Last Posted Date: 2024-08-13

Lead Sponsor: Washington State University

Target Recruit Count: 205

Registration Number: NCT05134857

Locations: 🇺🇸
Washington State University, Spokane, Washington, United States

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

Phase 3

Completed

Conditions: Smoking Cessation

Interventions: Drug: Zonisamide
Drug: Bupropion
Other: Halo G6 e-cigarette

First Posted Date: 2020-05-14

Last Posted Date: 2022-04-13

Lead Sponsor: Rose Research Center, LLC

Target Recruit Count: 26

Registration Number: NCT04388319

Locations: 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States

Zonisamide Outpatient Study

Phase 2

Withdrawn

Conditions: Post Traumatic Stress Disorder
Alcohol Use Disorder

Interventions: Drug: Zonisamide
Drug: Placebo Comparator

First Posted Date: 2017-12-18

Last Posted Date: 2021-03-09

Lead Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

Registration Number: NCT03376139

Locations: 🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States

Population Pharmacokinetics of Antiepileptic in Pediatrics

First Posted Date: 2017-06-22

Last Posted Date: 2024-10-30

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 1000

Registration Number: NCT03196466

Locations: 🇫🇷
AP-HP Cochin, Paris, France

Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

Phase 3

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Zonisamide
Drug: Placebo (for Zonisamide)
Behavioral: Take Control

First Posted Date: 2016-09-15

Last Posted Date: 2023-06-18

Lead Sponsor: Boston University Charles River Campus

Target Recruit Count: 81

Registration Number: NCT02901041

Locations: 🇺🇸
Center for Anxiety and Related Disorders - Boston University, Boston, Massachusetts, United States

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

Phase 3

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2016-09-14

Last Posted Date: 2022-10-13

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 156

Registration Number: NCT02900352

Locations: 🇺🇸
UCONN Health, Farmington, Connecticut, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
West Haven Veterans Affairs, West Haven, Connecticut, United States

and more 1 locations

Effectiveness of Zonisamide in Alcohol Dependent Veterans

Phase 3

Terminated

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Zonisamide

First Posted Date: 2015-02-23

Last Posted Date: 2020-12-07

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 92

Registration Number: NCT02368431

Locations: 🇺🇸
VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States

Prevention of Noise-induced Hearing Loss

Phase 1

Withdrawn

Conditions: Noise-induced Hearing Loss

Interventions: Drug: Zonisamide
Drug: Methylprednisolone

First Posted Date: 2014-01-29

Last Posted Date: 2017-11-06

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT02049073

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy